StreetInsider.com News Articles

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

Tue, 03 Mar 2026 16:30:00 -0500

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET.

A live webcast and recording of this presentation will be available from the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Events”. Archived webcasts will be available for approximately 30 days following

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

Tue, 03 Mar 2026 16:30:00 -0500

Form 6-K ProQR Therapeutics N.V. For: Feb 09

Mon, 09 Feb 2026 08:07:00 -0500

si-local-file:///var/storage/secattach/20260209/25965223.html

Form 6-K ProQR Therapeutics N.V. For: Feb 09

Mon, 09 Feb 2026 08:07:00 -0500

si-local-file:///var/storage/secattach/20260209/25965223.html

ProQR announces board changes as two directors to step down

Mon, 09 Feb 2026 08:00:15 -0500

ProQR Therapeutics N.V. (NASDAQ: PRQR) announced that two board members will step down at the company's next annual general meeting when their terms conclude.

Dinko Valerio, a co-founder of the clinical-stage RNA therapy company, and Alison Lawton will rotate off the board. The Netherlands-based company said the changes reflect its development as it advances clinical programs and ongoing corporate governance practices.

ProQR has engaged an executive search firm to identify candidates for nomination to the board. The company said this process aims to support long-term value creation for stakeholders.

"On behalf of the Board, I would like to sincerely thank Dinko for his

ProQR Announces Planned Changes to Board Composition

Mon, 09 Feb 2026 08:00:00 -0500

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting (AGM) as their terms conclude.

The planned changes to ProQR’s Board composition at its 2026 AGM reflect the Company’s development as it advances its clinical programs, as well as its ongoing commitment to strong corporate

ProQR Announces Planned Changes to Board Composition

Mon, 09 Feb 2026 08:00:00 -0500

The planned changes to ProQR’s Board composition at its 2026 AGM reflect the Company’s development as it advances its clinical programs, as well as its ongoing commitment to strong corporate

Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V.

Fri, 06 Feb 2026 16:01:00 -0500

si-local-file:///var/storage/secattach/20260206/25961375.html

Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V.

Fri, 06 Feb 2026 16:01:00 -0500

si-local-file:///var/storage/secattach/20260206/25961375.html

Form SCHEDULE 13G ProQR Therapeutics N.V. Filed by: Privium Fund Management B.V.

Tue, 20 Jan 2026 17:22:00 -0500

si-local-file:///var/storage/secattach/20260120/25869391.html

Form SCHEDULE 13G ProQR Therapeutics N.V. Filed by: Privium Fund Management B.V.

Tue, 20 Jan 2026 17:22:00 -0500

si-local-file:///var/storage/secattach/20260120/25869391.html

Form 6-K ProQR Therapeutics N.V. For: Jan 08

Thu, 08 Jan 2026 08:09:00 -0500

si-local-file:///var/storage/secattach/20260108/25823491.html

Form 6-K ProQR Therapeutics N.V. For: Jan 08

Thu, 08 Jan 2026 08:09:00 -0500

si-local-file:///var/storage/secattach/20260108/25823491.html

ProQR reports initial AX-0810 safety data, selects development candidates

Thu, 08 Jan 2026 08:00:14 -0500

ProQR Therapeutics N.V. (NASDAQ: PRQR) announced preliminary safety and pharmacokinetic data from its Phase 1 trial of AX-0810, an investigational RNA editing therapy for cholestatic diseases. The company reported no serious adverse events or clinically meaningful laboratory abnormalities in the first cohort of healthy volunteers after four weeks of dosing at 3mg/kg.

The ongoing Phase 1 study is evaluating AX-0810 in up to 33 participants across three dose cohorts, with 24 receiving the active drug and nine receiving placebo. Participants receive four subcutaneous injections over four weeks followed by a 12-week safety follow-up period. The company expects to report target engagement

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Thu, 08 Jan 2026 08:00:00 -0500

Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohort
Development Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)
Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, contributing to strong financial position with runway into mid-2027

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) --
ProQR Therapeutics N.V.

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Thu, 08 Jan 2026 08:00:00 -0500

Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohort
Development Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)
Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, contributing to strong financial position with runway into mid-2027

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) --
ProQR Therapeutics N.V.

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Mon, 01 Dec 2025 08:00:00 -0500

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20am ET.

Webcast details will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under "Events". Archived webcasts will be available for approximately 30 days following the presentation

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Mon, 01 Dec 2025 08:00:00 -0500

ProQR Announces Third Quarter 2025 Operating and Financial Results

Thu, 06 Nov 2025 07:00:00 -0500

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseases
Initiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagement data from all cohorts in H1 2026
€ 106.9 million cash and cash equivalents as of end Q3 – providing runway into mid-2027

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its

ProQR Announces Third Quarter 2025 Operating and Financial Results

Thu, 06 Nov 2025 07:00:00 -0500

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseases
Initiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagement data from all cohorts in H1 2026
€ 106.9 million cash and cash equivalents as of end Q3 – providing runway into mid-2027

Form 6-K ProQR Therapeutics N.V. For: Sep 30

Thu, 06 Nov 2025 07:00:00 -0500

si-local-file:///var/storage/secattach/20251106/25566015.html

Form 6-K ProQR Therapeutics N.V. For: Sep 30

Thu, 06 Nov 2025 07:00:00 -0500

si-local-file:///var/storage/secattach/20251106/25566015.html

Form 6-K ProQR Therapeutics N.V. For: Nov 03

Mon, 03 Nov 2025 16:02:00 -0500

si-local-file:///var/storage/secattach/20251103/25544699.html

Form 6-K ProQR Therapeutics N.V. For: Nov 03

Mon, 03 Nov 2025 16:02:00 -0500

si-local-file:///var/storage/secattach/20251103/25544699.html

Citizens Reiterates ProQR Therapeutics N.V. (PRQR) at Market Outperform Ahead of Phase 1 Readout

Fri, 24 Oct 2025 06:08:28 -0500

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $8.00 price target on ProQR Therapeutics N.V. (NASDAQ: PRQR).

The analyst commented, "Earlier this week, we hosted an investor dinner in New York with ProQR, where investors were eager to discuss the upcoming Phase 1 readout and its implications for AX-0810’s development path; we reiterate our Market Outperform rating and $8 price target based on our risk-adjusted, sum-of-the-parts analysis."

For an analyst ratings summary and ratings history on ProQR Therapeutics N.V. click here. For more ratings news on ProQR Therapeutics N.V. click here.

Shares of ProQR Therapeutics N.V. closed at $2.82